Suppr超能文献

LLE-HPLC-PDA-MS/MS 在药物代谢研究中的分析能力:鉴定新的萘丁美酮代谢物。

Analytical power of LLE-HPLC-PDA-MS/MS in drug metabolism studies: identification of new nabumetone metabolites.

机构信息

Institute of Experimental Biopharmaceutics, Joint Research Center of PRO.MED.CS Praha a.s. and Academy of Sciences of the Czech Republic, Heyrovského 1207, CZ-500 02 Hradec Králové, Czech Republic.

出版信息

J Pharm Biomed Anal. 2013 Jun;80:164-72. doi: 10.1016/j.jpba.2013.03.006. Epub 2013 Mar 19.

Abstract

Nabumetone is a non-acidic, nonsteroidal anti-inflammatory prodrug. Following oral administration, the prodrug is converted in the liver to 6-methoxy-2-naphthylacetic acid (6-MNA), which was found to be the principal metabolite responsible for the NSAID effect. The pathway of nabumetone transformation to 6-MNA has not been clarified, with no intermediates between nabumetone and 6-MNA having been identified to date. In this study, a new, as yet unreported phase I metabolite was discovered within the evaluation of nabumetone metabolism by human and rat liver microsomal fractions. Extracts from the biomatrices were subjected to chiral LLE-HPLC-PDA and achiral LLE-UHPLC-MS/MS analyses to elucidate the chemical structure of this metabolite. UHPLC-MS/MS experiments detected the presence of a structure corresponding to elemental composition C15H16O3, which was tentatively assigned as a hydroxylated nabumetone. Identical nabumetone and HO-nabumetone UV spectra obtained from the PDA detector ruled out the presence of the hydroxy group in the aromatic moiety of nabumetone. Hence, the most likely structure of the new metabolite was 4-(6-methoxy-2-naphthyl)-3-hydroxybutan-2-one (3-hydroxy nabumetone). To confirm this structure, the standard of this nabumetone metabolite was synthesized, its spectral (UV, CD, NMR, MS/MS) and retention properties on chiral and achiral chromatographic columns were evaluated and compared with those of the authentic nabumetone metabolite. To elucidate the subsequent biotransformation of 3-hydroxy nabumetone, the compound was used as a substrate in incubation with human and rat liver microsomal fraction. A number of 3-hydroxy nabumetone metabolites (products of conjugation with glucuronic acid, O-desmethylation, carbonyl reduction and their combination) were discovered in the extracts from the incubated microsomes using LLE-HPLC-PDA-MS/MS experiments. On the other hand, when 3-hydroxy nabumetone was incubated with isolated rat hepatocytes, 6-MNA was detected as the principal metabolite of 3-hydroxy nabumetone. Hence, 3-hydroxy nabumetone could be the missing link in nabumetone biotransformation to 6-MNA (i.e. nabumetone→3-hydroxy nabumetone→6-MNA).

摘要

萘丁美酮是一种非酸性、非甾体抗炎前药。口服给药后,前药在肝脏中转化为 6-甲氧基-2-萘乙酸(6-MNA),6-MNA 是负责 NSAID 作用的主要代谢物。萘丁美酮转化为 6-MNA 的途径尚未阐明,迄今为止尚未发现萘丁美酮和 6-MNA 之间的任何中间产物。在这项研究中,在人肝微粒体和鼠肝微粒体部分评估萘丁美酮代谢物时,发现了一种新的、尚未报道的 I 相代谢物。从生物基质中提取的样品进行手性 LLE-HPLC-PDA 和非手性 LLE-UHPLC-MS/MS 分析,以阐明该代谢物的化学结构。UHPLC-MS/MS 实验检测到存在对应于元素组成 C15H16O3 的结构,该结构被暂定鉴定为羟化萘丁美酮。从 PDA 检测器获得的相同的萘丁美酮和 HO-萘丁美酮 UV 光谱排除了萘丁美酮芳环部分存在羟基的可能性。因此,新代谢物最可能的结构是 4-(6-甲氧基-2-萘基)-3-羟基丁-2-酮(3-羟基萘丁美酮)。为了确认该结构,合成了该萘丁美酮代谢物的标准品,评估并比较了其光谱(UV、CD、NMR、MS/MS)和在手性和非手性色谱柱上的保留特性与真实的萘丁美酮代谢物。为了阐明 3-羟基萘丁美酮的后续生物转化,将该化合物用作与人肝微粒体和鼠肝微粒体孵育的底物。使用 LLE-HPLC-PDA-MS/MS 实验从孵育的微粒体提取物中发现了许多 3-羟基萘丁美酮代谢物(与葡萄糖醛酸结合、O-脱甲基、羰基还原及其组合的产物)。另一方面,当 3-羟基萘丁美酮与分离的大鼠肝细胞孵育时,检测到 6-MNA 是 3-羟基萘丁美酮的主要代谢物。因此,3-羟基萘丁美酮可能是萘丁美酮转化为 6-MNA 的缺失环节(即萘丁美酮→3-羟基萘丁美酮→6-MNA)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验